A phase 1, randomized, double-blind, placebo-controlled assessment of the safety, tolerability, and activity of GS-9191 ointment for the treatment of external genital and perianal warts caused by human papilloma virus infection
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2009
At a glance
- Drugs GS 9191 (Primary)
- Indications Genital warts
- Focus Therapeutic Use
- 14 Apr 2009 Actual end date (Mar 2009) added, actual patient number (202) added as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.